drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous anti-GPRC5D chimeric antigen receptor (CAR) T-cell therapy in which the patient’s T cells are genetically modified to express a CAR targeting GPRC5D on malignant plasma cells; upon antigen engagement, CAR-T cells activate, proliferate, release cytokines, and kill target cells. Given as a single infusion after lymphodepletion for relapsed/refractory multiple myeloma or primary plasma cell leukemia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express a chimeric antigen receptor targeting GPRC5D on malignant plasma cells; upon antigen binding, CAR T cells activate, proliferate, release cytokines, and kill target cells via perforin/granzyme-mediated cytotoxicity.
drug_name
CT071
nct_id_drug_ref
NCT06333509